scispace - formally typeset
N

Noel S. Weiss

Researcher at University of Washington

Publications -  641
Citations -  43475

Noel S. Weiss is an academic researcher from University of Washington. The author has contributed to research in topics: Population & Cancer. The author has an hindex of 105, co-authored 630 publications receiving 40550 citations. Previous affiliations of Noel S. Weiss include University of Bern & United States Department of Veterans Affairs.

Papers
More filters
Journal ArticleDOI

A case-control study of screening sigmoidoscopy and mortality from colorectal cancer.

TL;DR: Screening by sigmoidoscopy can reduce mortality from cancer of the rectum and distal colon and a screening once every 10 years may be nearly as efficacious as more frequent screening.
Journal ArticleDOI

Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis

TL;DR: Low-dose diuretics are the most effective first-line treatment for preventing the occurrence of cardiovascular disease morbidity and mortality and future trials should use low-doseDiuretics as the standard for clinically useful comparisons.
Journal ArticleDOI

The Risk of Myocardial Infarction Associated With Antihypertensive Drug Therapies

TL;DR: The findings of this study support the current guidelines from the Joint National Committee on the Detection, Evaluation and Treatment of High Blood Pressure that recommend diuretics and beta-blockers as first-line agents unless contraindicated, unacceptable, or not tolerated.
Journal ArticleDOI

Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States

TL;DR: Prevalence of DKD in the United States increased from 1988 to 2008 in proportion to the prevalence of diabetes, and was stable despite increased use of glucose-lowering medications and renin-angiotensin-aldosterone system inhibitors among persons with diabetes.
Journal ArticleDOI

Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen.

TL;DR: It is argued that lowering of the risk of hip and forearm fractures must be weighed as a benefit of long-term estrogen use.